Condition
Non-specific Effects of Vaccines
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
100%
5 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
P 3 (2)
P 4 (3)
Trial Status
Completed2
Unknown2
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07005726Phase 4Enrolling By Invitation
BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa
NCT04542330Phase 3Completed
Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
NCT05397678Phase 4Unknown
Trial to Compare BCG-Bulgaria and BCG-Denmark
NCT04445428Phase 4Unknown
OPV as Potential Protection Against COVID-19
NCT04373291Phase 3Completed
Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic
Showing all 5 trials